Public Submissions on the Uganda National Biotechnology and Biosafety Bill, 2012 Reveal Potential Way Forward for Uganda Legislators to Pass the Bill by Clet Wandui Masiga
PERSPECTIVE
published: 06 October 2015
doi: 10.3389/fbioe.2015.00152
Edited by:
Karen Hokanson,
University of Minnesota, USA
Reviewed by:
Michael Wach,
International Life Sciences Institute
Research Foundation, USA
Mark E. Halsey,
Donald Danforth Plant Science
Center, USA
*Correspondence:
Clet Wandui Masiga,
Tropical Institute of Development
Innovations (TRIDI), Plot 8/9 Apollo
Close, Entebbe P. O. Box 493,
Entebbe, Uganda
c.masiga@tridi.org;
wmasiga@hotmail.com
Specialty section:
This article was submitted to
Biosafety and Biosecurity, a section of
the journal Frontiers in Bioengineering
and Biotechnology
Received: 28 March 2015
Accepted: 18 September 2015
Published: 06 October 2015
Citation:
Masiga CW (2015) Public
submissions on the Uganda National
Biotechnology and Biosafety Bill,
2012 reveal potential way forward for
Uganda legislators to pass the bill.
Front. Bioeng. Biotechnol. 3:152.
doi: 10.3389/fbioe.2015.00152
Public submissions on the Uganda
National Biotechnology and Biosafety
Bill, 2012 reveal potential way forward
for Uganda legislators to pass the bill
Clet Wandui Masiga*
Tropical Institute of Development Innovations, Entebbe, Uganda
The Cartagena Protocol on Biosafety to the Convention on Biological Diversity is an
internationally binding instrument addressing issues of biosafety. Biosafety refers to the
need to protect human health and the environment from the possible adverse effects of
the products of modern biotechnology. Accordingly, all countries to the convention are
required to put in place regulatory mechanisms to enhance the safety of biotechnology in
the context of the Convention’s overall goal of reducing all potential threats to biological
diversity, while taking into account the risks to human health. Therefore, each country
party to the convention has its own procedures to enact laws to guide the safe use
of biotechnology. In Uganda, the process involves the drafting of the bill by the first
parliamentary counsel, approval by cabinet, first reading at the parliament, committal to
the responsible parliamentary sessional committee, tabling of the bill for public hearing,
consultations, and final approval. In Uganda, the Committee on Science and Technology
is responsible for the Biosafety Bill. In March 2013, the Committee tabled the bill for public
hearing and submissions from public institutions. There were comments supporting the
passage of the Bill and comments in objection. The reasons for objection are mainly due
to precaution, speculation, lack of knowledge about biotechnology and biosafety, and
alleged influence from biosafety entrepreneurs. This article reviews these public views,
revealing controversy and possible consensus to pass the bill.
Keywords: biotechnology, biosafety, genetically modified, parliament, legislation, entrepreneur
Introduction
The modification of plants and animals to obtain new ones with traits desired by farmers has
been going on for millennia. It involved random recombination of DNA in offspring followed by
selection for traits best suited for food, fiber, feed, and energy production (Barrows et al., 2014). This
breeding was typically slow, sometimes limited by availability of desired traits in related species, and
often took decades and frequently yielded crop varieties with unforeseen and undesirable properties.
More recently, the process evolved to include the use of biotechnological techniques, particularly
genetic engineering, to reduce uncertainty and breeding time and to transfer traits from more
distantly related species (Andersson et al., 2014; James, 2014; Sharma et al., 2014). Biotechnology
encompasses any technique that uses living organisms or substances from such organisms tomake or
modify a product, to improve plants or animals, or to developmicro-organisms for specific purposes
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(Masiga et al., 2014). Plants and animals bred through genetic
engineering are normally referred to as genetically modified
organisms (GMOs).
In some countries, the adoption of GMOs has occurred with
little objection, whereas in others, there has been fierce con-
troversy (Stone, 2010). The origin of this controversy seems to
have been partly legitimized through international biosafety legal
instruments, the Convention on Biological Diversity (CBD), and
the Cartagena Protocol on Biosafety (CPB). The CPB required
each signatory to put in place a national legal framework for safe
development and commercialization of GMOs. As a consequence,
most countries in Africa have either put in place, or are working
to develop, legal frameworks for development and deployment of
GMOs.
Each country party to the convention has its own procedures
to enact laws. In Uganda, the process involves the drafting of the
bill by the first parliamentary counsel, approval by cabinet, first
reading at the parliament, committal to the responsible parlia-
mentary sessional committee, tabling of the bill for public hearing,
consultations, and final approval. The process for drafting the
bill started in 1997 with the drafting of the National Biosafety
Framework (NBF) to ensure safety in biotechnology. This was
approved in March 2001 and in the same year the guidelines
on biosafety in biotechnology were developed. This was followed
with the establishment of the National Coordinating Committee
(NCC) in 2002 to revise and publish biosafety guidelines, which
was later followed by the drafting of the national policy on biotech-
nology and biosafety in 2003. The draft policy was later subjected
to several consultations, reviews, and inputs from experts and in
April 2008, it was approved by Cabinet. In the same year, the
approved policy in turn led to the development of a draft Biosafety
Bill. In March 2013, the bill was tabled by the parliamentary
Committee on Science and Technology for public hearing and
submissions from public institutions. The submissions were both
for and against the bill.
This polarization of opinion indicated a need to better inform
the public regarding the technology. This would help to clarify or
amplify points of divergence (Juma, 2003). In 2013, to build capac-
ity for Ugandans to support a bill, a world-renowned authority on
the role of innovation in economic development Prof. Calestous
Juma was invited to give a public lecture on the use of science and
engineering for rapid economic transformation. In this article,
I present views from the online submissions that lasted from
19th April 2013 to 8th October 2013 following the public lecture.
The issues raised and their clarifications have parallels with those
against and in favor of adoption of GMOs, except the facts on
either side are often skewed to influence the debate in their own
direction. Several of the “anti” positions are based on emotion, and
may be countered by scientific literature or facts. The next section
presents the main categories of arguments submitted.
International Obligations
Those against the bill claimed that it does not conform to inter-
national obligations set out in the CPB (United Nations Environ-
mental Programme (UNEP), 2000) and the CBD (United Nations
Environmental Programme (UNEP), 1992). Those promoting it
insist the bill has been prepared in response to the international
obligations and has all relevant sections required by the protocol
and the misinformation arises from the different interpretations
of the clauses and deliberate twisting of facts. Clause 29 of the
bill emphasizes safety in using biotechnology by providing for
measures to be taken to minimize or avoid risk to human health
and the environment arising from actual or potential contact with
a GMO. Article 17 of the CPB requires Uganda to provide for
emergency measures to deal with unintentional release of a GMO.
Clause 30 gives effect to that obligation by requiring every applica-
tion for research or general release to contain an emergency plan
complete with safety measures to cater for circumstances where
a GMO is released unintentionally to the environment. It is also
important to note that the Protocol leaves significant flexibility
for implementing instruments at the national level, as shown by
many other countries (e.g., Kenya). Also, the scope of the Protocol
deals with transboundarymovement of livingmodified organisms
(LMOs) only, whereas national laws have a more comprehensive
scope. The argument whether a law does or does not follow the
Protocol is always difficult to interpret.
Scope of the Bill
Those against the bill claim that its scope is restrictive as it only
applies to general releases of GMOs and does not mention the full
range of activities involved. Those in favor insist that the bill is
clear on these issues and is in line with article 4 of the Cartagena
Protocol and therefore complies with the full range of activities,
including research, contained use, confined field trials, import,
export, and general release of a GMO (Government of Uganda,
2012).
The Objective of the Bill
One of the objectives of the bill is to facilitate the safe development
and application of biotechnology. Those against the bill have
indicated that this objective is to facilitate and not regulate the
introduction of GMOs in the country. If passed, it will create an
enabling policy environment to promote GMOs in the country.
Their intention is to restrict adoption of GMOs. Those for the
bill indicate that the CPB recognizes “that biotechnology has
great potential for human well-being if developed and used with
adequate safety.” Their intension is to have a bill that facilitates the
adoption ofGMOs.As such the promoters of the bill argue that the
objectives are in agreement with national agenda as well as meet-
ing international obligation as envisaged in the CPB and should
be done in a manner that does not disrupt trade (United Nations
Environmental Programme (UNEP), 2000; Excellence Through
Stewardship, 2015). There are many studies that currently favor
the use of GMOs in increasing food, fuel, and fiber production
(Wieczorek, 2003; Kwiecinski, 2009; Chipman, 2010; Jeanes, 2013;
Kuntz et al., 2013; Nature, 2013).
The Precautionary Principle
Those against the bill argue that the precautionary principle
should prevail until sufficient evidence becomes available to prove
that GMOs are safe. The promoters interpret the principle tomean
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that if you are not absolutely sure about the safety of a GMO, you
can make a decision to use it. A review of the relevance of the
precautionary principle in risk assessment confirms the divergent
views about its application, which allows opposite conclusions
depending on the context (Juma and Honca, 2002; Saner, 2002).
Publication of the Application
The bill requires a notice in the prescribed form of the application
for general release of the GMO to be published in the Gazette and
the official website of the Competent Authority.
Opponents of the bill have indicated that after receipt of appli-
cation, it should also be published in all local newspapers. Those
promoting GMOs observe that the publication of the applica-
tion follows other government procedures otherwise it will set a
precedence that is against the constitution and other government
laws.
Expedited Review
The bill highlights circumstances when it is necessary for the
Competent Authority to expedite the review of an application for
research or general release of a GMO. Those against the bill argue
that it provides for expedited review of an application where a
competent authority of another country has previously approved
the GMO in comparable ecosystems. They recommend that this
provision should be stricken from the bill because there are no
two ecosystems that are similar and that the risk of GMOs should
be carried out on a case-by-case basis. Proponents argue that this
provision is in line with the current harmonization of policies to
facilitate regional trade.
Liability and Redress
The bill provides for offenses and penalties to any person and
corporate bodies. Those against the bill argue that it does not
specifically address who will be responsible for the liability. They
believe that the liability and redress system as provided for in the
bill has been vaguely defined to give protection to the multina-
tional corporations that will be promoting their technologies and
ignore the rights of farmers. They also believe that the bill provides
for a fault-based liability principle instead of a strict liability
approach. Those in favor argued that liability and redress are well
covered through other legal instruments. They also argue that
strict liability is shallow, vague, envious, and a political argument
and has been overtaken by time.
Public Participation
Those against the bill argue that it does not provide an elaborate
public participationmechanism. It onlymandates that the compe-
tent authority promote awareness and does not specify the rights
of the public to participate in the decision-making process. Those
in favor of the bill have argued that scientific facts should not be
subjected to a debate where one side must win and that, pub-
lic participation is incorporated into the Biosafety Bill following
international best practices.
Labeling
Those against the bill argue that it does not have an explicit
provision on labeling to allow for consumers to have a choice.
Those in favor argue that the labeling is not necessary because
it will either increase the cost of those farmers producing GMOs
or traders of the GM foods. It will also be extremely difficult to
enforce such a law asmost agricultural trade inUganda is informal
and it is not easy to trace a product to one particular farmer.
Patents and Rights
Those against the bill argue that GMOs will increase farmer costs
because GM seeds are patented, which affects farmer practices
to save, share, and multiply seed in interests of sustaining food
systems. They believe that farmers’ right to save and replant saved
seeds will be lost due to patented GMO seeds. Those in favor
of GMOs argue that the costs associated with patents and rights
would not affect costs to farmers who choose not to use the
technology.
Use of Publications and Pseudoscience
Both sides cited published literature that favored their view of the
argument, and each side discounted the other’s choices of sup-
porting documentation. For example, those against the bill have
made gooduse of anti-GMOreports andpublications to back their
claims to resist GMOs. Those promoting GMOs believe that these
negative publications are authored by biosafety entrepreneurs for
business and career development.
Anti-GMO activists have relied on flawed publications to reject
the bill. For example, they have used a publication reporting
that rats fed on a lifelong diet of a common strain of genetically
modified corn developed tumors and severe damage to their liver
and kidneys (Séralini et al., 2012). A reviewof the publication indi-
cated serious weakness of design, conduct, and analysis and was
subsequently retracted (Séralini et al., 2014a,b). Another publica-
tion that is largely used to reject the bill is the one concluding that
contrary to often-repeated claims that today’s genetically engi-
neered (GE) crops reduce pesticide use, the spread of glyphosate-
resistant weeds in herbicide-resistant weed management systems
has brought about substantial increases in the number and volume
of herbicides applied (Benbrook, 2012). Review of this paper
showed that it was flawed being based on inaccurate claims, biased
assumptions, and misleading use of official data (Brookes et al.,
2012).
Economic Argument
Rejection of the bill is also based on Schnurr (2013), who pub-
lished that there is network of corporate actors, development
agencies, policy officials, and research scientists that support the
unquestioned dominance of GM in Uganda. GMO research and
commercialization is driven by donors and has nothing to do with
local demand (Schnurr and Gore, 2015). Those to the contrary
argue that the technical and infrastructural capacity that has been
built in Uganda is designed to enable Ugandans to develop and
commercialize GMOs that are safe for humans, the environment,
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and biodiversity. They argue that it is false that farmers do not
need GMOs and that these GM technologies are not demand
driven. The approach used for GMO development and commer-
cialization is not different from any other breeding technique in
the country.
Bribes by Multinationals
There is a perception that legislators, government civil servants,
cabinet officials, scientists, academics, journalists, and any other
person who see benefits in GMOs for mankind have been paid by
Monsanto to market their products. Those promoting GMOs also
argue thatmost of those against GMOs are receiving funding from
the Environmental GrantMakers Association to block adoption of
GMOs and are in it for business and interest of their funders.
Capacity for GMO Development and
Management
Anti-GMO groups believe that there is inadequate scientific
knowledge within Africa. So, this particular scientific “adven-
ture” is simply wrong. Therefore, Africa is not ready at all for
these GMOs, given African infrastructure, technology, literacy
levels, capacity in terms of risk assessment, environmental protec-
tion, etc. Those supporting the bill argued that Uganda has built
significant human and infrastructural capacity to handle GMOs.
There are more than 140 Ugandan scientists working in agri-
cultural biotechnology and more than 15 Ugandan institutions
conducting biotechnology research, including public and privately
owned businesses (International Food Policy Research Institute
(IFPRI), 2013).
Unexpected Resistance to Herbicides and
Emergence of Superweeds
Those against the bill argue that GMOs have led to unexpected
resistance to herbicides and emergence of superweeds plus the
huge expenses associated with managing the superweeds as a
result of herbicide tolerant technology. Promoters, on the other
hand, argue that this is a natural trend and not specific to GMOs.
There are four historical and biological examples that were used
to illustrate this point, which include the story of industrial
melanism in England involving the peppered moth (Kettlewell,
1955), resistance to antibiotics, fungicides/insecticides, and heavy
metal resistance in plants.
Conspiracy Theories
Those against the bill believe that GMO promoters are under a
conspiracy to shorten the life span of Africans. So unlike in Africa,
where GMOs will be consumed directly, GM corn produced in
the US and other countries is converted into high-fructose corn
syrup or used in other industrial processes that break down GE
crop components into ethanol/biodiesel and vegetable oils or fed
to livestock. GMO proponents argue that there are a number of
credible studies done on the safety of GMOs that have indicated
that there is no significant difference between the safety of GMOs
and non-GMOs.
Market for Farm Produce
Some GMO opponents are worried that Uganda may lose market
access for their farm produce if the country adopts GMOs. They
believe that foreign markets that are uninterested in the GMOs
will not buy farm produce from countries growing GMOs, hence
resulting in a significant loss for the farmers. To the contrary, those
in favor of GMOs believe that Europe, which has been the main
block against GMOs, imports a lot of food from countries that
grow GMOs.
Main Agricultural Constraint is not
Production
Those against the bill believe that the problem facing farming
in Uganda is not production but other constraints, such as post-
harvest handling, processing, and distribution. The proponents
believe that GMOs are used to target specific traits in response to
specific challenges, particularly those that have not been possible
to address using conventional means.
Conclusion and Way Forward
There have been, and will continue to be, public debate about
GMOs. But considering the submissions from the two sides of the
arguments, the bill is clear on its objectives and it conforms to the
requirements of the international obligations, as the crux of the
argument for going forward. The Bill as it is neither promotes nor
prohibits the technology, but it ensures that it will be used only
when regulators determine it is safe. Both sides of the argument
should be able to support that. A law that addresses all concerns
of the people is very unlikely. And as such themost feasible option
is to take it as it is and then revise it as the country uses it. In
its current state, the bill appears to allow the adoption of GMOs
while ensuring that they are safe to humans, biodiversity, and the
environment.
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